AIkido Pharma Executes Licensing Agreement with University of Maryland

COV-IRT member Matthew Frieman is one of the University of Maryland inventors on this project.


NEW YORK, April 21, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on April 13, 2020, the Company executed a Master License Agreement (the “License Agreement”) with the University of Maryland, Baltimore (“UMB”). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.

The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson.  The Company has also executed a Sponsored Research Agreement with UMB to support the development of the technology.

Mr. Anthony Hayes, CEO of AIkido, stated, “We are excited to move forward with this new antiviral platform.  The pedigree of the inventors and the institution is first rate.  We believe the doctors and UMB are both leaders in the field and are frequently cited in major publications discussing viruses generally, as well as COVID-19.  We are proud to partner with them in this critical undertaking.”

Read Full Article

Share this post